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Late Anthracycline-Related Cardiotoxicity in Low-Risk Breast Cancer Patients 
 
Anthracyclines improve survival in breast cancer, but can cause cardiotoxicity, manifest either as overt 
clinical heart failure or asymptomatic left ventricular dysfunction. Determining cardiotoxicity prevalence is 
difficult; definitions vary, presentation may be delayed, and risk varies by chemotherapy regime and dose, 
and with cardiovascular comorbidities. Guidance regarding the optimal frequency and duration of long-
term monitoring for cardiovascular toxicity is, therefore, lacking. 
 
We sought to assess late anthracycline cardiotoxicity in low-risk breast cancer survivors receiving standard 
anthracyclines, using multimodality imaging: cardiovascular MR imaging for left ventricular volume, 
ejection fraction (LVEF), tissue characterization including fibrosis quantification, and advanced 
echocardiography for early cardiac dysfunction. 
 
Subjects recruited to a previous study of early anthracycline cardiotoxicity, the BETTER-CARE study (BC) (1), 
were invited to participate. This study investigated cardiotoxicity pathogenesis in patients with no prior 
cancer history, free from pre-existing cardiovascular risk factors or disease, treated for early stage breast 
cancer, and all patients underwent standard CMR imaging before chemotherapy, including late gadolinium 
enhancement imaging. Investigations at follow-up included repeat cardiac MR (with sequences 
standardized with the baseline scan), additional acquisition of modified Look Locker inversion recovery T1 
maps to generate extracellular volume maps using blood hematocrit (2), echocardiography (tissue Doppler 
and speckle tracking-derived strain measures), as well as blood biomarkers. Clinical outcomes were 
obtained from electronic patient records and patient questionnaires, and from death certificates. Female 
healthy volunteers (HV) of similar age were recruited for comparison (n ¼ 34). Research had appropriate 
ethical approvals and written informed consent. Between-group comparisons were undertaken using the 
Student t test for continuous variables, and by chi-square or Fisher exact test for categorical variables. 
 
Of the 166 original BC participants, 25 (15%) had cancer recurrence/metastases (10 deaths). Two subjects 
died from noncardiovascular, nononcological causes. Ninety-eight subjects (mean age: 55.0 + 8.5 years) 
underwent follow-up imaging at a mean of 6.0+ 1.2 years after the first anthracycline dose. Anthracycline 
doses were considerably below levels considered high risk; the mean cumulative epirubicin dose was 
399+85 mg/m2. Twenty-five percent of subjects also received trastuzumab, 73% hormonal therapy, and 
84% radiotherapy (51% left sided/whole chest). 
 
At follow-up, all patients were free from cardiovascular symptoms and signs. None had ever received a 
heart failure diagnosis. Overall, absolute LVEF decreased by a mean of 3.7+4.2% (range: -13% to 8%), with 
reductions of 10% or more in 8 subjects. However, because LVEF remained >55% in all, none met criteria 
for cancer therapy-related cardiac dysfunction (3). Reductions in the LVEF were no greater in subjects 
exposed to radiotherapy or trastuzumab, although those receiving higher anthracycline doses (>450 mg/m2 
of epirubicin) had greater interval change (-4.6 +3.7% vs. -2.7+4.4%; p ¼ 0.030) (Figure 1). Left ventricular 
volumes, mass, and LVEF were similar in HV and BC subjects at follow-up, and no subjects had a significant 
scar on late enhancement imaging.  
 
Myocardial septal extracellular volume was similar between groups (BC vs. HV: 0.28 + 0.028 vs. 0.28 + 
0.029; p  0.803); however, native myocardial T1 was marginally higher in the BC group compared to the HV 
(1,052 _ 30 ms vs. 1,037 _ 31 ms; p ¼ 0.012). Compared with HV, the BC cohort had slightly worse tissue 
Doppler indices of function and global longitudinal and radial strain, and higher values of N-terminal pro–B-
type natriuretic peptide (9.97 + 1.93 pmol/l vs. 7.32 + 1.90 pmol/l; p 0.024), but again, all values fell within 
normal ranges. 
Using multimodality technologies in a low-risk population followed for 6 years, standard anthracycline 
chemotherapy caused no clinically significant cardiotoxic effects (no cardiovascular deaths, heart failure 
events, or decreases in function sufficient to meet cancer therapy-related cardiac dysfunction criteria). 
There were small, dose-related changes in cardiac function when compared with HV, but these modest 
cardiac changes compare with 15% cancer recurrence, including 6% who died. This is an imbalance; in low-
risk patients, the risk of late cardiotoxicity seems to be small compared with tumor recurrence and 
progression risk. 
 
Most previous anthracycline cardiotoxicity studies used short follow-up, and assume that function 
decreases linearly with time. Early (2-year) assessments of cardiotoxicity in the complete BC cohort found 
frequent subtle changes in LVEF (LVEF reductions $5% in 21% of subjects) (1); however, these current 
results are reassuring and align with previous evidence following 2625 subjects for more 
than 5 years, where 98% of cardiotoxicity occurred in the first year (4). Allowing for potential survival bias 
(follow-up of the complete baseline cohort was impossible), these findings support focusing screening on 
early detection of cardiotoxicity, with late follow-up confined to high-risk groups. 
 
 
CMR BC (n=98) HV* (n=34) P value 
LVEDV-1, ml/m2 66+8 66+10 0.792 
LVESV-1, ml/m2 21+4 21+5 0.821 
LVEF, % 68+5 68+4 0.414 
Native myocardial T1, 
ms 
1052+30 1037+31 0.012 
ECV 0.28+0.028 0.28+0.029 0.803 
Echocardiography BC (n=93) ECHOHV* (n=33)  
Mean E’ tissue Doppler 
velocity, m/s 
0.11+0.02 0.12+0.03 0.009 
E/E’ ratio 6.11+1.56 6.32+1.79 0.52 
GLS, % -22.2+1.80 -23.3+1.46 0.002 
GRS, % 39.2+13.7 50.0+11.8 <0.001 
Figure 1: The BETTER-CARE (BC) Study recruited 166 breast cancer subjects at low cardiovascular risk 
receiving anthracycline chemotherapy, all of whom underwent cardiac magnetic resonance (CMR)) at baseline before 
chemotherapy. Six years later, 98 subjects underwent comprehensive cardiovascular follow-up including CMR, T1 
mapping, advanced echocardiography, and blood biomarkers. There were small (but detectable) differences between 
some imaging parameters in BC subjects and healthy controls. AC – anthracycline dose; ECHOLV- echo healthy 
volunteers; ECV- extracorporeal volume; GLS- global longitudinal strain; GRS- global radial strain; HV- healthy 
volunteers; LVEDV- left ventricular end-diastolic volume; LVEF left ventricular ejection fraction; LVESV- left ventricular 
end-systolic volume.  
*CMR healthy volunteer (HV) and echo healthy volunteer (ECHOHV) differed. 
Clinical outcomes at 6 years following anthracycline chemotherapy: Cancer (25 recurrence, 10 deaths), cardiovascular 
(0 heart failure events, 0 deaths). 
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